Stent wars at TCT 2012: Drug-eluting stents maintain lead over bare-metal

Tue, 10/23/2012 - 5:10pm
Mass Device

Next-generation drug-eluting stents continue to maintain a lead over their bare-metal cousins as researchers unveil more studies at this week's Transcatheter Cardiovascular Therapeutics meeting.

TCT 2012 logo

With new and next-generation stents gaining ground over their forebears, the stent wars don't look to be letting up anytime soon.

The battle continued at the Transcatheter Cardiovascular Therapeutics meeting this week, where pooled results from a pair of studies further affirmed that next-generation drug-eluting stents demonstrate better safety and efficiency at 1 year compared to bare-metal stents.

Researchers combined data from the Examination and Comfortable AMI studies, which comprised a total of more than 2,600 patients, to look for larger trends in the DES vs. BMS battle.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.